Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial

Archives of Cardiovascular Diseases

Volumn 102, Issue 6-7, 2009, Pages 485-496

  Collet, Jean Philippe ^a   Montalescot, Gilles ^a   Steg, Philippe Gabriel ^b   Steinhubl, Steven R ^c   Fox, Keith A A ^d   Hu, Ting Fei ^e   Johnston, S Claiborne ^f   Hamm, Christian W ^g   Bhatt, Deepak L ^h   Topol, Eric J ⁱ  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Kerchoff Heart Center   (Germany)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Acute coronary syndrome; Atherothrombosis; Clopidogrel; Rebound

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HUMAN; INSTRUMENTATION; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PLACEBO EFFECT; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT; RISK FACTOR; SAFETY; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CARDIOVASCULAR DISEASES; CONSUMER PRODUCT SAFETY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PLACEBO EFFECT; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 72949106125     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2009.03.012     Document Type: Article

References (29)

1. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.
2. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
3. Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. (Pubitemid 35340537)
4. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
5. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-3. (Pubitemid 34408881)
6. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667-74. (Pubitemid 44729867)
7. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004;110:2361-7. (Pubitemid 39407340)
8. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2006 [published online: Dec 5, 2006: doi:10.1001/jama.297.2.joc60179].
9. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000;35:1288-94. (Pubitemid 30206904)
10. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91. (Pubitemid 44881238)
11. Vicenzi MN, Meislitzer T, Heitzinger B, et al. Coronary artery stenting and non-cardiac surgery - a prospective outcome study. Br J Anaesth 2006;96:686-93. (Pubitemid 43786682)
12. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61. (Pubitemid 44826931)
13. Roiron C, Sanchez P, Bouzamondo A, et al. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006;92:641-9.
14. Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72. (Pubitemid 43947981)
15. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9. (Pubitemid 44305292)
16. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
17. Allen La Pointe NM, Kramer JM, DeLong ER, et al. Patient-reported frequency of taking aspirin in a population with coronary artery disease. Am J Cardiol 2002;89:1042-6. (Pubitemid 34462847)
18. Granger BB, Swedberg K, Ekman I, et al. Adherence to can-desartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005;366:2005-11. (Pubitemid 41773375)
19. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-7. (Pubitemid 44455166)
20. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-72. (Pubitemid 36258718)
21. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-9. (Pubitemid 351222546)
22. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the verify thrombosis risk assessment (VERITAS) study. Thromb Res 2007;119:277-84. (Pubitemid 44918092)
23. Collet JP, Montalescot G. Premature withdrawal and alternative therapies to dual oral antiplatelet therapy. Eur Heart J 2006;8(Suppl. G):G46-52. (Pubitemid 44526986)
24. Schouten O, van Domburg RT, Bax JJ, et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007;49: 122-4. (Pubitemid 46026891)
25. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9. (Pubitemid 46376803)
26. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9. (Pubitemid 46376802)
27. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-97. (Pubitemid 46376799)
28. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
29. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49: 1982-8. (Pubitemid 46694290)